SCHEMBL5046835

SCHEMBL5046835

CSc1ccc(C#Cc2ccc3c(c2)OCC(C)(C)CO3)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 5/20 0.51
ALDH1A1 P00352 4/20 0.36
LMNA P02545 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TP53 P04637 3/20 0.32
NPC1 O15118 2/20 0.32
MAPT P10636 2/20 0.32
RAB9A P51151 2/20 0.32
POLB P06746 2/20 0.32
TSHR P16473 2/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
PKM P14618 1/20 0.32
GRM5 P41594 2/20 0.31
S1PR5 Q9H228 1/20 0.31
KDM4E B2RXH2 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046911 0.83 ACACB (0.53) ACACBALDH1A1POLB
SCHEMBL5046845 0.82 ACACB (0.56) ACACBNPC1MAPTRAB9AGRM5
SCHEMBL5043437 0.79 ACACB (0.51) ACACBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5043723 0.78 ACACB (0.48) ACACBGRM5
SCHEMBL5046684 0.77 ACACB (0.61) ACACBALDH1A1MEN1KMT2ANPC1
SCHEMBL5043403 0.77 ACACB (0.52) ACACBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5046540 0.77 ACACB (0.48) ACACBGRM5
SCHEMBL5043671 0.75 ACACB (0.50) ACACBSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL5048104 0.74 ACACB (0.45) ACACB
SCHEMBL5046909 0.74 ACACB (0.55) ACACBALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US claimed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP claimed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US claimed
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US disclosed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP disclosed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113374-A1 Benzodioxepine derivatives BBOX1, ACOX1, ACOX3 ACACB 5/4885ALDH1A1 361/4885LMNA 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.